Regeneron Pharmaceuticals

Capital allocation is driven by the co-founders: CEO Leonard Schleifer sets the strategic direction, while President and Chief Scientific Officer George Yancopoulos oversees the research pipeline. Major R&D and partnership commitments are authorized by the board, but the company’s science-forward posture means Yancopoulos’s team effectively decides which drug candidates advance.

Regeneron’s pipeline originates almost entirely from its own target-discovery work. The Regeneron Genetics Center has sequenced over 3 million exomes, linking genetic variants to disease phenotypes. Targets identified there are fed into the VelociSuite technology platform to produce fully human antibodies, a process that systematically generates candidates for clinical testing.

No. It operates as a fully integrated pharmaceutical company. It does not raise outside funds, charge management fees, or syndicate risk through VC-style spinouts. Instead, it self-funds R&D from commercial revenues and co-development agreements, most notably the global partnership with Sanofi on Dupixent.

Regeneron does not publicly declare strict sector exclusions. Its current pipeline focuses on eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, and infectious diseases. It has not disclosed active programs in areas such as reproductive health or consumer medical devices.